+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

The lupus inhibitor its heterogeneity

Thrombosis & Haemostasis 46(4): 734-739

The lupus inhibitor its heterogeneity

The plasmas of 6 patients with prolonged activated partial thromboplastin times were studied in detail. In 5 of the 6, the Russell's viper venom and prothrombin times were likewise prolonged. Five of the patients had documented systemic lupus erythematosus; one lacked the necessary criteria for this diagnosis. On quantitation, factor XI was decreased in all 6; factors X and XII were diminished in 5 of the 6. When tested for inhibitory activity, plasma from each of the patients prolonged the celite eluate inhibition test for factor XII and/or XI inhibition. In the formation of the factor Xa-factor V-phospholipid-Ca2+ complex (prothrombinase), factors X and Xa were inhibited to a greater degree than factor V or the phospholipid. Finally, each plasma was isofocused, the inhibitory fractions were identified and the clotting factor specificity of each inhibitory peak was determined. Fractions inhibitory against factors XI and XII isofocused with the IgG in each patient's plasma. The lupus inhibitor is apparently a heterogeneous collection of inhibitors directed against factors XII, XI and X rather than a homogeneous entity.

(PDF 0-2 workdays service: $29.90)

Accession: 006712445

Related references

The lupus inhibitor: a study of its heterogeneity. Thrombosis and Haemostasis 46(4): 734-739, 1981

Heterogeneity and diversity of IgM and IgG lupus anticoagulants in an individual with systemic lupus erythematosus. Biochemical and Biophysical Research Communications 203(3): 1789-1794, 1994

Biological and clinical heterogeneity of lupus and lupus-like anticoagulant in fifty-seven patients. Journal of Medicine 18(3-4): 199-217, 1987

Antibody to C1-inhibitor in a patient receiving C1-inhibitor infusions for treatment of hereditary angioneurotic edema with systemic lupus erythematosus reacts with a normal allotype of residue 458 of C1-inhibitor. Journal Of Laboratory & Clinical Medicine. 128(4): 438-443, 1996

Recurrent venous thrombosis with a "lupus" coagulation inhibitor in the absence of systemic lupus. Australian and New Zealand Journal of Medicine 7(4): 422-426, 1977

The lupus inhibitor in thromboembolic disease and intrauterine death in the absence of systemic lupus. Acta Medica Scandinavica 215(4): 293-298, 1984

Circulating lupus coagulation inhibitor in two sisters, one with disseminated lupus erythematosus and the other with immunologic thrombocytopenic purpura. La Revue de Medecine Interne 13(4): 305-306, 1992

High amounts of tissue factor pathway inhibitor in lupus patients and the relationships with lupus activity and damage. Arthritis & Rheumatism 41(9 SUPPL ): S218, Sept, 1998

Test heterogeneity of the lupus anticoagulant Comparison of various La test in 102 cases of systemic lupus erythematosus. Fibrinolysis 10(SUPPL 3): 100, 1996

Levels of tissue factor pathway inhibitor in lupus patients correlate with lupus activity and endothelial damage markers. Haematologica 87(11): 1231-1232, 2002